Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

Inclusion Criteria: * Participants with history of CAD or participants categorized in 'high risk' by Japan Atherosclerosis Society (JAS) 2017 guidelines or participants with heterozygous familial hypercholesterolemia (HeFH) * As per the JAS 2017 guideline, participants not meeting the LDL-C management targets. * Participants on statins should be receiving a maximally tolerated dose. * Participants not receiving statins must have documented evidence of intolerance to at least one statin. * The lipid-lowering therapy should have remained stable for ≥ 30 days before screening with no planned medication/ dose change until Day 180 Exclusion Criteria: * Participants diagnosed with homozygous familial hypercholesterolemia (HoFH). * Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9. * New York Heart Association (NYHA) class IV heart failure or last known left ventricular ejection fraction \<25%. * Cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation. * Uncontrolled hypertension: systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg prior to randomization despite antihypertensive therapy. * Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at screen…